Adoption of new cancer drugs requires careful consideration of their benefits, toxicities, and costs. Patient experiences are rarely considered in trial design and drug-approval processes. Challenges ...

SAN DIEGO, CA / ACCESS Newswire / January 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or ...

Phase 1/2a study with lead Radio-DARPin MP0712 initiated; first patient dosing expected Q1 2026, initial data anticipated in 2026Full imaging and dosimetry data from MP0712 compassionate care program ...

Tubulis today announced the appointment of Charles Fuchs, MD, as Chief Medical Officer (CMO). Dr. Fuchs is an internationally ...

Phase I human study and preclinical evaluations of OcuRing™-K showed no treatment-related safety concerns, supporting ...

To that end, biomarkers are proposed to measure the delivery of drugs to their intended targets, and to understand and predict pathophysiology, and how it is altered by therapy, through monitoring ...

As 2026 begins, a slate of high-stakes clinical readouts—from a pivotal study of Novartis’ cardiovascular candidate ...

No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following ...

Over the past decade, a shift has been occurring in biopharma R&D. Despite great advancements in drug technologies and our understanding of diseases, it is getting harder to develop new drugs and ...

Advances in our understanding of cancer biology have led to the discovery of a spectrum of new therapeutic targets. However, despite remarkable progress in the identification and characterization of ...

A systematic approach that views the clinical research department as an integral part of the development team can enhance the likelihood of success in the creation of new products. Nancy J. Stark Many ...

Instil Bio said its subsidiary has discontinued clinical development of AXN-2510 and terminated its collaboration agreement with ImmuneOnco Biopharmaceuticals (Shanghai) for AXN-2510 and AXN-27M.